Emphasizing the importance of evaluating the big picture when it comes to diagnostic testing, David C. Collymore, MD, MBA, said, “When we think about genomic testing, and when we consider the total cost of care for oncology treatment, it may seem like it’s increasing the cost of care. But if we can get to a point where our outcomes are improved—although it may be a financial increase in terms of cost—if we can save lives, then the overall effect is positive.”
Rationalizing the expense that may be associated with diagnostic testing, Dr Collymore explained that it’s essential to move beyond the actual cost of care and start thinking about, “are we improving quality of life, are we saving lives, are we curing cancers…that really should be the focus,” he said.
“If done right, we will eventually get to a point where we’ll encounter cost savings. With genetic and genomic testing, if we can see a decrease in the incidence of cancer, it’s a tremendous cost saving,” said Dr Collymore. He strongly believes that even with an increase in the total cost of care per patient, if genomic testing can have an impact on the overall population, it will prove economically feasible for a healthcare system.
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More